# Rituximab in Auto-Immune Hemolytic Anemia

> **NCT01181154** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 32 (actual)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** rituximab (Mabthera®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01181154
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-03
- **Primary completion:** 2015-01-08
- **Final completion:** 2016-01-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01181154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01181154, "Rituximab in Auto-Immune Hemolytic Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01181154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*